RECRUITING

Autologous Adipose Cells Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.

Official Title

Autologous Adipose Cells Therapy

Quick Facts

Study Start:2025-05-01
Study Completion:2025-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06869252

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Outpatients who express interest in skin rejuvenation, and/or who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.
  2. 2. Outpatients who are experiencing hair loss or hair thinning
  3. 3. Provision of signed and dated informed consent form
  4. 4. Clearly stated willingness to comply with all the procedures of the study and availability of the study
  5. 5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor
  1. 1. Pregnancy or lactation
  2. 2. Known allergic reaction to components of cell culture media
  3. 3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures
  4. 4. Chronic infections, e.g. skin fungi infection, psoriasis
  5. 5. Chronic wound healing
  6. 6. Currently taking hormone therapy
  7. 7. History of cancers and active cancers
  8. 8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.

Contacts and Locations

Study Contact

Ankeet Dixit
CONTACT
813-992-2521
ankeetdixit@cermbio.com
Wing Nam Fung
CONTACT
207-671-9370
wingnam@bioprostheticscorp.com

Principal Investigator

Dr. Abdollah M. Malekzadeh, MD, MD
PRINCIPAL_INVESTIGATOR
The Centre for Cosmetic Surgery & Medicine
Dr. Arun Kumar, PhD
STUDY_DIRECTOR
CERM INC.

Study Locations (Sites)

The Centre for Cosmetic Surgery & Medicine, Newark
Lewes, Delaware, 19958
United States
The Centre for Cosmetic Surgery & Medicine
Newark, Delaware, 19713
United States

Collaborators and Investigators

Sponsor: CERM INC.

  • Dr. Abdollah M. Malekzadeh, MD, MD, PRINCIPAL_INVESTIGATOR, The Centre for Cosmetic Surgery & Medicine
  • Dr. Arun Kumar, PhD, STUDY_DIRECTOR, CERM INC.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-01
Study Completion Date2025-11-01

Study Record Updates

Study Start Date2025-05-01
Study Completion Date2025-11-01

Terms related to this study

Additional Relevant MeSH Terms

  • Hair Loss/Baldness
  • Wrinkle Appearance
  • Volume
  • Fine Lines
  • Skin Elasticity
  • Hair Thinning
  • Skin Pigmentation
  • Skin Texture